RT Journal Article
SR Electronic
T1 Predictive utility of mortality by aging measures at different hierarchical levels and the response to modifiable lifestyle factors: Implications for geroprotective programs
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.27.21266932
DO 10.1101/2021.11.27.21266932
A1 Zhang, Jingyun
A1 Cao, Xingqi
A1 Chen, Chen
A1 He, Liu
A1 Ren, Ziyang
A1 Xiao, Junhua
A1 Han, Liyuan
A1 Wu, Xifeng
A1 Liu, Zuyun
YR 2021
UL http://medrxiv.org/content/early/2021/11/28/2021.11.27.21266932.abstract
AB Background Aging, as a multi-dimensional process, can be measured at different hierarchical levels including biological, phenotypic, and functional levels. The aims of this study were to: 1) compare the predictive utility of mortality by three aging measures at three hierarchical levels; 2) develop a composite aging measure that integrated aging measures at different hierarchical levels; and 3) evaluate the response of these aging measures to modifiable lifestyle factors.Methods Data from National Health and Nutrition Examination Survey 1999-2002 were used. Three aging measures included telomere length (TL, biological level), Phenotypic Age (PA, phenotypic level), and frailty index (FI, functional level). Mortality information was collected until Dec. 2015. Cox proportional hazards regression and multiple linear regression models were performed.Results A total of 3249 participants (20-84 years) were included. Both accelerations (accounting for chronological age) of PA and FI were significantly associated with mortality, with HRs of 1.67 (95% confidence interval [CI] = 1.41-1.98) and 1.59 (95% CI = 1.35-1.87), respectively, while that of TL showed nonsignificant associations. We thus developed a new composite aging measure (named PC1) integrating the accelerations of PA and FI, and demonstrated its better predictive utility relative to each single aging measure. PC1, as well as the accelerations of PA and FI, were responsive to several lifestyle factors.Conclusion The findings, for the first time, provide a full picture of the predictive utility of mortality by three aging measures at three hierarchical levels and the response to modifiable lifestyle factors, with important implications for geroprotective programs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding This research was supported by a grant from the National Natural Science Foundation of China (82171584), the 2020 Milstein Medical Asian American Partnership Foundation Irma and Paul Milstein Program for Senior Health project award (ZL), the Fundamental Research Funds for the Central Universities, a project from the Natural Science Foundation of Zhejiang Province (LQ21H260003), and fundings from Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province (2020E10004), Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2019R01007), Key Research and Development Program of Zhejiang Province (2020C03002), and Zhejiang University Global Partnership Fund (188170-11103). The funders had no role in the study design; data collection, analysis, or interpretation; in the writing of the report; or in the decision to submit the article for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available human data, which can be obtained from:https://www.cdc.gov/nchs/nhanes/index.htmI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at: https://www.cdc.gov/nchs/nhanes/index.htm https://www.cdc.gov/nchs/nhanes/index.htm